Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Sage Therapeutics to Present at 2022 Stifel CNS Days

March 22, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease

March 15, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Expert Ratings For Sage Therapeutics ↗

February 25, 2022

Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress

February 24, 2022

From Sage Therapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

December 20, 2021

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

February 17, 2022

On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...

Via Benzinga

56 Biggest Movers From Yesterday ↗

February 17, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...

Via Benzinga

Why A Biogen-Sage Drug Flopped — And Could Still Be Approved ↗

February 16, 2022

The companies tested a combination of zuranolone and depression drugs.

Via Investor's Business Daily

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 16, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...

Via Benzinga

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study ↗

February 16, 2022

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 16, 2022

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

February 16, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

February 10, 2022

From Sage Therapeutics, Inc.

Via Business Wire

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022

January 04, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S. ↗

December 28, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 27, 2021

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...

Via Benzinga

Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises

December 14, 2021

From Sage Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress

December 08, 2021

From Sage Therapeutics, Inc.

Via Business Wire

5 Value Stocks To Watch In The Healthcare Sector ↗

December 06, 2021

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples...

Via Benzinga

Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients ↗

December 01, 2021

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...

Via Benzinga

The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case ↗

December 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...

Via Benzinga

Topics Intellectual Property

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

December 01, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Host Sage FutureCast Webcast

November 29, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 24, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

November 11, 2021

From Sage Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 08, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) ...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.